Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Antidepressant Effects of Low-Dose Intravenous Esketamine in Patients with Chronic Pain
ChiCTR2500111749Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in chronic pain and major depressive disorder (MDD) (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: General signs and Beck Depression Inventory (BDI, self-rating scale). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
chronic painmajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500111749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111749.